🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

31+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 11 of 31 recruiting trials for “Beta-thalassemia”

NARecruitingNCT06219239 ↗

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

🏥 Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jan 2024View details ↗
Phase 2RecruitingNCT07292259 ↗

Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia

👨‍⚕️ Tariq Ghafoor, FCPS,FRCP, National Institute of Blood and Marrow Transplant (NIBMT), Pakistan📍 9 sites📅 Started Jan 2024View details ↗
NARecruitingNCT05773729 ↗

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

👨‍⚕️ Chen Jing, M.D., Shanghai Children's Medical Center📍 1 site📅 Started Sep 2023View details ↗
Phase 2RecruitingNCT05693909 ↗

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

👨‍⚕️ Pharmacosmos Clinical and non-clinical Department, Pharmacosmos A/S📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT05991336 ↗

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

🏥 Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jun 2023View details ↗
EARLY_Phase 1RecruitingNCT05762510 ↗

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]

🏥 First Affiliated Hospital of Guangxi Medical University📍 1 site📅 Started Feb 2023View details ↗
Phase 1, PHASE2Enrolling by InvitationNCT05577312 ↗

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

👨‍⚕️ Xiaochen Wang, PhD, Bioray Laboratories📍 4 sites📅 Started Nov 2022View details ↗
RecruitingNCT05508932 ↗

Atrial Fibrillation in Beta-Thalassemia

🏥 University Hospital of Ferrara📍 1 site📅 Started Sep 2022View details ↗
Phase 3RecruitingNCT05477563 ↗

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

🏥 Vertex Pharmaceuticals Incorporated📍 6 sites📅 Started Aug 2022View details ↗
EARLY_Phase 1RecruitingNCT05745532 ↗

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

👨‍⚕️ Chao Liu, PHD, Shenzhen Hemogen📍 1 site📅 Started Dec 2020View details ↗
Phase 2RecruitingNCT04143724 ↗

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

👨‍⚕️ Bristol-Myers Squibb, Bristol-Myers Squibb📍 26 sites📅 Started Nov 2019View details ↗
← PreviousPage 2 of 2

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →